CN109251956A - The adjustment effect of MyD88 mRNA expression and Radix Astragali in diabetes rat pancreas islet - Google Patents
The adjustment effect of MyD88 mRNA expression and Radix Astragali in diabetes rat pancreas islet Download PDFInfo
- Publication number
- CN109251956A CN109251956A CN201811097414.5A CN201811097414A CN109251956A CN 109251956 A CN109251956 A CN 109251956A CN 201811097414 A CN201811097414 A CN 201811097414A CN 109251956 A CN109251956 A CN 109251956A
- Authority
- CN
- China
- Prior art keywords
- islet
- pancreas
- diabetes
- expression
- myd88 mrna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/19—Growth and differentiation factors [GDF]
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses the expression and Radix Astragali adjustment effect of diabetes pancreas islet MyD88 mRNA, the expression of the diabetes pancreas islet MyD88 mRNA gene of STZ induction is obviously increased, the horizontal significant raising of iNOS.Astragalus injection described in prolonged application can not only be such that the expression of T1DM pancreas islet MyD88 mRNA gene lowers, and it is horizontal to can reduce tail of pancreas tissue iNOS.There is obvious apoptosis in T1DM beta Cell of islet, and prolonged application astragalus injection can reverse the tune of T1DM beta Cell of islet to die.The mechanism of action of Astragalus in Treating diabetes can be expressed with pancreas islet MyD88 mRNA is lowered, and reduced tail of pancreas iNOS level, inhibited islet beta-cell apoptosis related.The beneficial effects of the invention are as follows provide certain theoretical foundation for the further the Molecular Biology Mechanism of research onset diabetes mechanism and Astragalus in Treating diabetes.
Description
Technical field
The invention belongs to pharmaceutical technology fields, are related to diabetes rat islet tissue MyD88 (Myeloid
Differentiation factor marrow sample differentiation factor) mRNA (Messenger ribonucleic acid courier's ribose core
Acid) expression and Radix Astragali regulating and controlling effect.
Background technique
Diabetes are a kind of disease of multifactorial inheritance, closely related with patient lifestyle, living environment, have been seriously threatened
Human health.The main clinical manifestation that blood glucose rise, diet increase, hydrouria, weight loss are diabetic, is commonly called as:
" three-many-one-little ", prolonged illness can involve the multisystems organ such as eye, kidney, peripheral nerve, seriously affect the quality of life of patient, even
Threaten the life of patient.The pathogenesis for studying diabetes, seeks the drug of the treatment diabetes of high-efficiency low-toxicity, it has also become current
One of critical task of medical field.
Type 1 diabetes (T1DM) are the chronic auto-immune diseases that T cell mediates, it is broken with beta Cell of islet specificity
Bad to be characterized, the major way of β cytoclasis is the Apoptosis of immune induction.The generation of T1DM and body autoimmunity are adjusted
It is unbalance closely related, after body loses tolerance to a variety of Islet Antigen ingredients, major histocompatibility complex (MHC)-II
The bone-marrow-derived lymphocyte antigen that class molecule is handled with it activates Th1 subgroup, inhibition Th2 subgroup in helper lymphocyte T jointly,
Pathogenic T h1 cell/cell factor is set to have comparative advantage compared with protectiveness Th2 cell/cell factor, and then activating cytotoxic T
Cell, macrophage, natural killer cells generate oxygen radical, nitric oxide, cell factor (IL-1 β, TNF-α, IFN-γ
Deng), beta Cell of islet is killed by approach such as NF- κ b, FAS-FASL, eventually leads to the generation of T1DM.
Cell factor IL-1 β, TNF-α are very strong to beta Cell of islet lethality, and IFN-γ helps out, wherein IL-1 β
The NO that inducing islet β cell itself generates is great to having an effect for its apoptosis, and prompts to may be by nuclear factor-interleukin
1 receptor (IL-1R) signal transduction pathway plays cytotoxicity.IL-1R once receives to stimulate (IL-1 β, IL-18 etc.) will be with
Adaptor protein marrow sample differentiation factor (MyD88) combines, and MyD88 recruits downstream albumen and transmits signal downwards, drops I κ b phosphorylation
Solution, and separated with NF- κ b, while NF- κ b is activated into core, with nitricoxide synthase (iNOS Inducible NO synthase)
κ b sequence in gene promoter combines, and promotes the transcription of iNOS, generates more NO and mediates β Apoptosis.MyD88 exists at present
IL-1R signal pathway transduction still under study for action.
MyD88, a kind of important symbol of previously described bone marrow differentiation are widely present in more than 50 lifes such as the mankind, muroid
Species category, the mankind MyD88 assignment of genes gene mapping is in No. 3 chromosome p21.3-p22, 296 amino acid are encoded, MyD88 structure height is protected
It keeps, is made of 5 exons and 4 intrones, wherein first exons coding aminoterminal death domain (death
Domain, DD), second exons coding intermediate region, last 3 exons codings c-terminus TIR structural domain, these three knots
Structure domain constitutes the benchmark architecture of MyD88.Carboxyl terminal has one section of highly conserved sequence, with the TLR of the drosophila and IL-1R of people
Certain section of sequence it is very much like, therefore referred to as TIR structural domain.Interaction between MyD88, IL-1R and IL-1RACP is just
It is to be realized by the interaction of three's homology TIR structural domain.DD is the knot being made of about 90 amino acid
Structure domain interacts between mediating proteins, and the DD structural domain of most of albumen is located at carboxyl terminal, and MyD88, IRAK and fruit
DD in the protein pipe of fly is but in amino terminal.The research of MyD88 gene knockout confirms that MyD88 is in TLR/IL-1R signal transduction
Center, IL-1R signal transduction is completely dependent on MyD88 to mediate.
Radix Astragali is help class Chinese medicine, is the root of leguminous plant Astragalus membranacus and astragalus mongolicus, and sweet in flavor, slightly warm in nature has and mends
The effect of gas lift sun, invigorating qi for consolidating superficies, inducing diuresis to remove edema, promoting pus discharge and tissue regeneration.Radix Astragali mainly contains flavones, polysaccharide, glucoside, amino acid, constant
And the Multiple components such as microelement.The effective component of astragalus injection is astragalus polyose, it is to cellular immunity, humoral immunity, non-
The activity of specific immune function and cell factor has adjustment effect, while NOD mouse Th1/Th2 type cell can also be inhibited to lose
Weighing apparatus state converts the reaction of Th2 type cell/cell factor dominance for the autoimmune response based on Th1 type, for T1DM
Prevention and treatment have certain effect.
Summary of the invention
The purpose of the present invention is to provide the expression and Radix Astragali adjustment effect of MyD88 mRNA in glycosuria rat disease pancreas islet, originally
Advantageous effect of the invention is further to study the Molecular Biology Mechanism of onset diabetes mechanism and Astragalus in Treating diabetes and mentioning
For certain theoretical foundation.
The obvious up-regulation of MyD88 mRNA expression, iNOS level also significantly increase in the diabetic rat pancreas of STZ induction.
Further, prolonged application astragalus injection can not only be such that the expression of T1DM pancreas islet MyD88 mRNA gene lowers, and
And it is horizontal to can reduce iNOS in tail of pancreas tissue.
Further, there is obvious apoptosis in T1DM beta Cell of islet, and intraperitoneal injection astragalus injection can partially reverse T1DM pancreas
The tune of island β cell is died.
Further, the mechanism of action of Astragalus in Treating diabetes can be expressed with pancreas islet MyD88 mRNA is lowered, and reduce tail of pancreas one
Nitric oxide synthase iNOS is horizontal, and the apoptosis for slowing down beta Cell of islet is related.
Detailed description of the invention
Fig. 1 is reverse effect-Electronic Speculum ultra microstructure of the Radix Astragali to diabetes rat islet beta-cell apoptosis.
Specific embodiment
The present invention is described in detail With reference to embodiment.
The research of the invention finds that streptozotocin (streptozotocin, STZ, ip, 55mgkg-1) induction glycosuria
The expression of sick rat Langerhans islet MyD88 mRNA gene obviously increases, the horizontal significant raising of iNOS.Prolonged application injects astragalus injection
The expression of T1DM pancreas islet MyD88 mRNA gene can not only be made to lower within liquid 21 days (ip, 2.5,5.0ml/kg/d), and can be dropped
Low tail of pancreas tissue iNOS is horizontal.Electronic Speculum the result shows that, there is obvious apoptosis, prolonged application astragalus injection in T1DM beta Cell of islet
The tune of T1DM beta Cell of islet can be partially reversed to die.The mechanism of action of Astragalus in Treating diabetes may be with downward pancreas islet MyD88
MRNA expression reduces tail of pancreas iNOS level, inhibits islet beta-cell apoptosis related.The following table 1 is Radix Astragali to T1DM blood glucose, serum pancreas
Island element and pancreas iNOS influence (n=10,).Table 2 is the influence (n=that Radix Astragali expresses T1DM pancreas islet MyD88 mRNA
10,)。
Table 1
*P < 0.05,**P<0.01vs control group；▲P<0.05vs T1DM group。
Table 2
*P < 0.05,**P<0.01vs control group；▲P<0.05vs T1DM group。
Fig. 1 is reverse effect-Electronic Speculum ultra microstructure of the Radix Astragali to diabetes rat islet beta-cell apoptosis.A1 and A2 in Fig. 1
It is normal rats beta Cell of islet, A1 (4.0k)-secretory granules are abundant in Fig. 1, and mitochondria, rough surfaced endoplasmic reticulum (RER) and Gorky are multiple
The organelles such as zoarium are intact；A2 (12.0k)-core inner periphery has obvious lumps heterochromatin, and organelle is intact, secretory granules compared with
It is more.B1 and B2 is beta cells of isolated rat islets, and lumps heterochromatin disappears in B1 (4.0k)-core, and cytoplasm inner cell organ occurs different
The degenerative change of degree, secretory granules, which have no, to be significantly reduced；B2 (15.0k)-mitochondrial cristae fracture, disorder, disappearance, vacuole sample
Become；The obvious degranulation of rough surfaced endoplasmic reticulum (RER)；The expansion of Golgi complex non-specificity.C1 and C2 is Radix Astragali group (5.0ml/ in Fig. 1
Kg/d) beta cells of isolated rat islets, C1 (4.0k)-core inner periphery reappear lumps heterochromatin, and most of Mitochondrial Shape is just
Often.There are still obvious vacuole samples to become for a small amount of mitochondria of C2 (15k)-.
Effect of the present invention research adaptor protein MyD88 in diabetes islet beta-cell apoptosis, and seen using transmission electron microscope
The change of beta Cell of islet ultra microstructure is examined, while giving Radix Astragali intervention, observes whether it has reverse immune imbalance, is lowered
MyD88 gene expression and the effect of anti-apoptotic.For point for further studying onset diabetes mechanism and Astragalus in Treating diabetes
Sub- biological mechanism provides certain theoretical foundation.
The above is only not to make limit in any form to the present invention to better embodiment of the invention
System, any simple modification that embodiment of above is made according to the technical essence of the invention, equivalent variations and modification,
Belong in the range of technical solution of the present invention.
Claims (4)
1. the expression and Radix Astragali adjustment effect of diabetes pancreas islet MyD88 mRNA, it is characterised in that: the diabetes pancreas islet of STZ induction
The expression of MyD88 mRNA gene obviously increases, the horizontal significant raising of iNOS.
2. according to the expression and Radix Astragali adjustment effect of diabetes pancreas islet MyD88 mRNA described in claim 1, it is characterised in that: long
Phase can not only be such that the expression of T1DM pancreas islet MyD88 mRNA gene lowers using astragalus injection, and can reduce tail of pancreas tissue
Interior iNOS is horizontal.
3. according to the expression and Radix Astragali adjustment effect of diabetes pancreas islet MyD88 mRNA described in claim 2, it is characterised in that: institute
It states T1DM beta Cell of islet and obvious apoptosis occurs, prolonged application astragalus injection can partially reverse the tune of T1DM beta Cell of islet
It dies.
4. according to the expression and Radix Astragali adjustment effect of diabetes pancreas islet MyD88 mRNA described in claim 2, it is characterised in that: institute
The mechanism of action for stating Astragalus in Treating diabetes can be expressed with pancreas islet MyD88 mRNA is lowered, and reduced tail of pancreas iNOS level, inhibited pancreas
Island β is apoptosis-related.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811097414.5A CN109251956A (en) | 2018-09-18 | 2018-09-18 | The adjustment effect of MyD88 mRNA expression and Radix Astragali in diabetes rat pancreas islet |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811097414.5A CN109251956A (en) | 2018-09-18 | 2018-09-18 | The adjustment effect of MyD88 mRNA expression and Radix Astragali in diabetes rat pancreas islet |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109251956A true CN109251956A (en) | 2019-01-22 |
Family
ID=65048508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811097414.5A Pending CN109251956A (en) | 2018-09-18 | 2018-09-18 | The adjustment effect of MyD88 mRNA expression and Radix Astragali in diabetes rat pancreas islet |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109251956A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102281880A (en) * | 2008-10-06 | 2011-12-14 | 艾德拉药物股份有限公司 | Use of inhibitors of toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and diseases related thereto |
| CN103874923A (en) * | 2011-08-26 | 2014-06-18 | 阿斯图特医药公司 | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| CN107243004A (en) * | 2017-04-26 | 2017-10-13 | 温州医科大学 | A kind of application of deoxyschizandrin in medicine preparation |
-
2018
- 2018-09-18 CN CN201811097414.5A patent/CN109251956A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102281880A (en) * | 2008-10-06 | 2011-12-14 | 艾德拉药物股份有限公司 | Use of inhibitors of toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and diseases related thereto |
| CN103874923A (en) * | 2011-08-26 | 2014-06-18 | 阿斯图特医药公司 | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| CN107243004A (en) * | 2017-04-26 | 2017-10-13 | 温州医科大学 | A kind of application of deoxyschizandrin in medicine preparation |
Non-Patent Citations (7)
| Title |
|---|
| DASU MR.等: "Increased toll-like receptor(TLR)activation and TLR ligands in recently diagnosed type2diabetic subjects", 《DIABETES CARE》 * |
| LIU P.等: "Expression and cellular distribution of TLR4, MyD88, and NF-κB in diabetic renal tubulointerstitial fibrosis, in vitro and in vivo", 《DIABETES RES CLIN PRACT.》 * |
| 张浩军等: "糖尿病肾病小鼠模型的研究现状 ", 《中国比较医学杂志》 * |
| 蒙向欣等: "加味芪黄饮调节TLR4/MyD88/NF-kB通路保护DKD模型大鼠肾功能的研究 ", 《内蒙古中医药》 * |
| 郑燕芳等: "石斛合剂对STZ损伤胰岛细胞的保护作用 ", 《福建中医药大学学报》 * |
| 陈腾 等: "黄芪治疗糖尿病肾病的研究进展", 《中国中西医结合肾病杂志》 * |
| 韩姣姣等: "1,25-二羟维生素D_3对糖尿病大鼠肺脏的保护作用及机制 ", 《山东医药》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Orsatti et al. | Propolis immunomodulatory action in vivo on Toll‐like receptors 2 and 4 expression and on pro‐inflammatory cytokines production in mice | |
| Wang et al. | A study on immunomodulatory mechanism of Polysaccharopeptide mediated by TLR4 signaling pathway | |
| Liu et al. | Orally administered Dendrobium officinale and its polysaccharides enhance immune functions in BALB/c mice | |
| Ganesan et al. | Dietary phytochemicals modulate intestinal epithelial barrier dysfunction and autoimmune diseases | |
| Fan et al. | Protective properties of combined fungal polysaccharides from Cordyceps sinensis and Ganoderma atrum on colon immune dysfunction | |
| EP2692352A1 (en) | Hot flash suppressant | |
| Sun et al. | The improvement of M1 polarization in macrophages by glycopeptide derived from Ganoderma lucidum | |
| CN102526479A (en) | Health-care medicine formula with functions of enhancing immunity and lowering blood sugar | |
| WO2019109551A1 (en) | Pharmaceutical composition containing magnesium aluminum carbonate and pharmaceutical use | |
| CN109251956A (en) | The adjustment effect of MyD88 mRNA expression and Radix Astragali in diabetes rat pancreas islet | |
| JP5808769B2 (en) | Subcutaneous fat accumulation inhibitor | |
| US8765115B2 (en) | Method of treatment of gastrointestinal disorders with IL-10 | |
| KR20120069221A (en) | Bee venom composition | |
| Qiao et al. | Effects of Hyriopsis cumingii polysaccharides on mice immunologic receptor, transcription factor, and cytokine | |
| CN105148257B (en) | Application of the hematopoietin source peptide in the drug of preparation treatment metabolic syndrome | |
| KR100506950B1 (en) | Immune stimulative constituents of ginseng saponins | |
| CN101596268B (en) | Application of garlic total saponin in preparing medicaments and foods for resisting oxidative stress damage | |
| CN101112405B (en) | Drug for curing coronary disease and method for preparing the same | |
| AU2021105645A4 (en) | Use of cornel iridoid glycoside in resisting diabetes mellitus | |
| CN114712481B (en) | Composite plant source polypeptide and preparation method and application thereof | |
| KR20120086919A (en) | Preparation method of germinated perilla seed oil | |
| CN109420157A (en) | A kind of application of pharmaceutical composition | |
| RU2814765C1 (en) | Method of treating ulcerative colitis | |
| Kadir et al. | Haematological effects of aqueous extract of Vernonia amygdalina and a known immunostimulant in Wistar rats | |
| CN107119074A (en) | It is a kind of to treat autoimmunity disease and the viral vector and its construction method of diabetes and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190122 |
|
| RJ01 | Rejection of invention patent application after publication |